Diyabetik maküla ödeminde intravitreal uygulanan anti-VEGF ajanlar ile intravitreal steroidlerin karşılaştırılması
Yükleniyor...
Dosyalar
Tarih
2015
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Hatay Mustafa Kemal Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
GiriĢ ve Amaç: Bu çalıĢmanın amacı diyabetik maküla ödemi(DMÖ)‟de sıkça kullanılan intravitreal ranibizumab ve bevacizumab tedavisinin intravitreal triamsinolon tedavi etkinliğiyle karĢılaĢtırılmasıdır. Gereç ve Yöntem: ÇalıĢmamıza fokal ya da diffüz DMÖ‟sü olup optik koherans tomografi(OCT) ile santral maküler kalınlığı 250 mikron üzerinde olan hastalar dahil edildi. Intravitreal 4 mg triamsinolon tedavisi alan 24 hastanın 30 gözü, 2.5 mg bevacizumab tedavisi alan 44 hastanın 45 gözü, 0.5 mg ranibizumab tedavisi alan 37 hastanın 45 gözü incelendi. Hastaların preoperatif ve postoperatif 1. ay ve 3. ay olmak üzere en iyi düzeltilmiĢ görme keskiniği(EĠDGK) ve santral maküler kalınlığı(SMK) ölçüldü. Bulgular: Triamsinolon grubunda preoperatif EĠDGK ortalaması 1,05±0,35(logMAR) iken, postoperatif 1.ay 0,79±0,36 ve 3.ay 0,81±0,35 olarak bulundu. Bevacizumab grubunda preoperatif EĠDGK ortalaması 0,58±0,41 iken, postoperatif 1.ay 0,44±0,49 ve 3.ay 0,38±0,30 olarak bulundu. Ranibizumab grubunda preoperatif EĠDGK ortalaması 0,70±0,39 iken, postoperatif 1.ay 0,41±0,29 ve 3.ay 0,38±0,28 olarak bulundu. Her 3 grupta preopratif değerler ile karĢılaĢtırıldığında görme keskinliği ve SMK değiĢimi anlamlı tespit edildi. Sonuç: Sonuç olarak DMÖ‟de intravitreal ranibizumab, bevacizumab ve triamsinolon tedavislerinin hepsi preoperatif değerler ile karĢılaĢtırıldığında görme keskinliğini arttırmakta ve santral maküler kalınlığı azaltmaktadırlar. Uzun dönemde ranibizumab anatomik ve görsel prognoz açısından daha etkili görünmektedir.
Background and aim: The purpose of this study,compare the efficacy of intravitreal triamcinolone with ranibizumab and bevacizumab that commonly used drugs in diabetic macular edema(DME). Material and method: We included the study patients who have focal or diffuse DME and central macular thickness above 250 microns in optical coherans tomography(OCT). 30 eyes of 24 patients that treated with intravitreal 4 mg triamsinolon,45 eyes of 44 patients that treated with 2,5 mg bevacizumab, 45 eyes of 37 patients that treated with 0,5 mg ranibizumab were examined. Preoperative and postoperative at month 1 and 3 best-corrected visual acuity(BCVA) and central macular thickness(CMT) were measured. Results: The preoperative mean BCVA was 1,05±0,35(logMAR), postoperative 0,79±0,36 at month 1 and 0,81±0,35 at month 3 in triamsinolon group. The preoperative mean BCVA was 0,58±0,41, postoperative 0,44±0,49 at month 1 and 0,38±0,30 at month 3 in bevacizumab group. The preoperative mean BCVA was 0,70±0,39, postoperative 0,41±0,29 at month 1 and 0,38±0,28 at month 3 in ranibizumab group. Visual acuity and CMT changes were detected significant when compared with preoperative values in all three groups. Conclusion: Consequently, all of intravitreal bevacizumab, ranibizumab, triamsinolon treatments increase the visual acuity and reduce the CMT when compared with preoperative values. Long-term anatomical and visual outcomes seem to be more effective in ranibizumab treatment.
Background and aim: The purpose of this study,compare the efficacy of intravitreal triamcinolone with ranibizumab and bevacizumab that commonly used drugs in diabetic macular edema(DME). Material and method: We included the study patients who have focal or diffuse DME and central macular thickness above 250 microns in optical coherans tomography(OCT). 30 eyes of 24 patients that treated with intravitreal 4 mg triamsinolon,45 eyes of 44 patients that treated with 2,5 mg bevacizumab, 45 eyes of 37 patients that treated with 0,5 mg ranibizumab were examined. Preoperative and postoperative at month 1 and 3 best-corrected visual acuity(BCVA) and central macular thickness(CMT) were measured. Results: The preoperative mean BCVA was 1,05±0,35(logMAR), postoperative 0,79±0,36 at month 1 and 0,81±0,35 at month 3 in triamsinolon group. The preoperative mean BCVA was 0,58±0,41, postoperative 0,44±0,49 at month 1 and 0,38±0,30 at month 3 in bevacizumab group. The preoperative mean BCVA was 0,70±0,39, postoperative 0,41±0,29 at month 1 and 0,38±0,28 at month 3 in ranibizumab group. Visual acuity and CMT changes were detected significant when compared with preoperative values in all three groups. Conclusion: Consequently, all of intravitreal bevacizumab, ranibizumab, triamsinolon treatments increase the visual acuity and reduce the CMT when compared with preoperative values. Long-term anatomical and visual outcomes seem to be more effective in ranibizumab treatment.
Açıklama
Anahtar Kelimeler
Göz Hastalıkları, Eye Diseases, Diyabetik maküla ödemi,triamsinolon, ranibizumab,bevacizumab., Diabetic macular edema, triamsinolon, ranibizumab, bevacizumab.
